NFKB1 and neoplasm: By affecting the host (systemic) metabolism, metformin could impair tumor cell growth and proliferation through reducing the blood glucose, insulin and IGF-1 levels, as well as through affecting the blood concentration of NFkB and pro-inflammatory cytokines and improving the anticancer immune response.